Erschienen in:
01.01.2013 | Original article
Lenalidomide enhances anti-myeloma cellular immunity
verfasst von:
Katarina Luptakova, Jacalyn Rosenblatt, Brett Glotzbecker, Heidi Mills, Dina Stroopinsky, Turner Kufe, Baldev Vasir, Jon Arnason, Dimitri Tzachanis, Jeffrey I. Zwicker, Robin M. Joyce, James D. Levine, Kenneth C. Anderson, Donald Kufe, David Avigan
Erschienen in:
Cancer Immunology, Immunotherapy
|
Ausgabe 1/2013
Einloggen, um Zugang zu erhalten
Abstract
Lenalidomide is an effective therapeutic agent for multiple myeloma that exhibits immunomodulatory properties including the activation of T and NK cells. The use of lenalidomide to reverse tumor-mediated immune suppression and amplify myeloma-specific immunity is currently being explored. In the present study, we examined the effect of lenalidomide on T-cell activation and its ability to amplify responses to a dendritic cell-based myeloma vaccine. We demonstrate that exposure to lenalidomide in the context of T-cell expansion with direct ligation of CD3/CD28 complex results in polarization toward a Th1 phenotype characterized by increased IFN-γ, but not IL-10 expression. In vitro exposure to lenalidomide resulted in decreased levels of regulatory T cells and a decrease in T-cell expression of the inhibitory marker, PD-1. Lenalidomide also enhanced T-cell proliferative responses to allogeneic DCs. Most significantly, lenalidomide treatment potentiated responses to the dendritic cell/myeloma fusion vaccine, which were characterized by increased production of inflammatory cytokines and increased cytotoxic lymphocyte-mediated lysis of autologous myeloma targets. These findings indicate that lenalidomide enhances the immunologic milieu in patients with myeloma by promoting T-cell proliferation and suppressing inhibitory factors, and thereby augmenting responses to a myeloma-specific tumor vaccine.